New marker found for the treatment of leukaemia patients
Patients suffering from acute myeloid leukaemia (AML) – a certain form of blood cancer – are treated with the help of chemotherapy. Often, the active substances Decitabine and Azacitidine – so-called DNA methyltransferase inhibitors – are used for older patients because those affected cannot tolerate intensive chemotherapy. But only some of the AML patients respond to this treatment. However, it is not yet possible to estimate which patients will benefit from these agents and which will not before starting therapy.
Supposedly equivalent drugs: important difference found
Recently, a multidisciplinary international team with cooperation partners from Germany, the USA and Great Britain carried out a study on this problem, which was funded by the Frankfurt Foundation for Children with Cancer and the association Hilfe für krebskranke Kinder Frankfurt. The scientists were able to show that the enzyme SAMHD1 converts the activated form of Decitabine back into its inactive initial form. This prevents therapeutic activity.
Interestingly, the effect of Azacitidine is not influenced by SAMHD1. The results, published under the title “Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML” in the renowned journal Nature Communications, show that there are significant differences between these drugs, which are often considered equivalent. Furthermore, the amount of SAMHD1 in AML cells as a marker could predict how sensitive they are to Decitabine. This is of potential clinical importance.
Frankfurt scientist in international research team
The research was led by Prof. Jindrich Cinatl from the University Hospital Frankfurt and Prof. Oliver Keppler from the Ludwig-Maximilians-University Munich. Numerous research groups from the Goethe University Frankfurt as well as scientists from the universities of Göttingen, Greifswald, Munich, Münster, Cambridge and Kent in Great Britain and Yale/USA were involved. The first author of the study, Prof. Thomas Oellerich from Goethe University, said of the results: “There is now justified hope that patients will benefit from these new research results in the foreseeable future.” Prof Oellerich holds a professorship of the German Consortium for Translational Cancer Research. Together with the University of Mainz, the University Hospital is a site of this health centre, which is funded by the Federal Ministry of Education and Research.
for children with cancer
Phone +49 (0)69 678665-0
Fax +49 (0)69 678665-94
Frankfurter Sparkasse 1822
IBAN: DE43 5005 0201 1245 6354 40
Click on the graphic below. You will be redirected to the Gooding site where you can shop in one of the more than 1,800 affiliated online shops. The participating shops support charitable organisations with a bonus of 5% of the purchase value on average. By logging in via the graphic, the Frankfurt Foundation for Children with Cancer is preselected as a premium recipient.
Click on the banner below. You will be taken to AmazonSmile, which is absolutely identical to your Amazon account. The only difference is that Amazon collects 0.5% of the order value for a charity of your choice. In the navigation bar on the left you can see which organisation your order supports. The "Frankfurter Stiftung für krebskranke Kinder" is already preselected by logging in via the banner.
© by Frankfurter Stiftung für krebskranke Kinder | powered by ONE AND O